Eli Lilly and Company

Kirk Willis Johnson

Lee A Phebus

Sandra Ann Filla

John M Schaus

Marlene L Cohen

James E Audia

John Joseph Mastrototaro

Theresa A Branchek

Paul Leslie Ornstein

James Allen Monn

Thomas Charles Britton

Steven Scott Henry

Darryle D Schoepp

David L Nelson

David Lipson

James W Heller

Joseph P Tizzano

Douglas J Allen

David Bleakman

Robert S Nevin

Michael Parvin Johnson

Gunnar Erik Jagdmann, Jr

Darrell Stephen Coleman

Thomas Hallett Large

Gudarz Davar

Robert Russell Conley

The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.

Chronic nightly dosing of lasmiditan for migraine prevention

The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.

Potentiators of glutamate receptors

The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR receptor antagonist. The present invention further provides novel compounds functional as selective iGluR receptor antagonists as well as compositions and formulations comprising said selective iGluR receptor antagonists.

Selective iGluR5 receptor antagonists for the treatment of migraine

This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a serotonin 5-HT agonist.

Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists

This invention provides 5-HT.sub.1F agonists of Formula I; ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.

5-HT.sub.1F agonists intermediates

This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a serotonin 5-HT.sub.1F agonist.

Methods of treating or ameliorating the symptoms of common cold or

This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.

Nitropyridine compound

This invention provides a method for the treatment or amelioration of the symptoms of venomous bites or stings which comprises administering to a mammal in need thereof one or more 5-HT.sub.2 antagonists.

Methods of treating or ameliorating the symptoms of venomous bites and

This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a 5-HT.sub.2 antagonist.

Method of treating or ameliorating the symptoms of common cold or

This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A--B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.

5-HT.sub.1F agonists

Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.

Serotonin agonist in combination with a tachykinin receptor antagonist

The present invention provides a method for the treatment of migraine with compounds or compositions that are selective agonists of 5-HT.sub.1F receptors relative to other serotonin receptors that produce unwanted effects like vasoconstriction. The neurogenic meningeal extravasation that leads to the pain of migraine is inhibited.

5-HT.sub.1F mediated inhibition of neurogenic meningeal extravasation: a

A method of improving the utility of electrochemical glucose sensors by decreasing either or both their settling time and their sensitivity to interfering compounds. In particular, the settling time of an electrochemical glucose sensor is improved by pretreating the operating electrode with a negative electric current at a constant current density. The sensor's sensitivity to intefering compounds is reduced by operating the sensor at a reduced voltage while the glucose concentration measurement is being made.

Techniques to improve the performance of electrochemical sensors

Homogeneous membranes permeable to oxygen and glucose composed of hydrophilic polyurethanes that are capable of absorbing from 10 to 50% of their dry weight of water. Variations in the composition of the hydrophilic polyurethanes make possible the fabrication of membranes in which the ratios of the diffusion coefficients of oxygen to glucose can be varied over a wide range. These membranes can be used in the fabrication of an electrochemical glucose sensor intended for use in vivo as an aid in the treatment of diabetes mellitus.

Hydrophilic polyurethane membranes for electrochemical glucose sensors

The present invention provides a method for immobilizing biomolecules on a conductive substrate to produce a biosensor.

Growing community of inventors

Carmel, IN, United States of America

Kirk Willis Johnson